TOMSICEK MICHAEL JOHN 4

What Happened Michael John Tomsicek, a director of Acrivon Therapeutics, was awarded 9,366 restricted stock units (RSUs) on May 18, 2026. The Form 4 reports an acquisition price of $0.00 (grant), so the filing lists $0 total cash paid; this reflects a compensation award, not a market purchase.

Key Details

• Transaction date: May 18, 2026; Form 4 filed May 20, 2026 (appears timely).
• Transaction type/code: Award/Grant (A).
• Shares/units granted: 9,366 RSUs; reported price $0.00 (grant).
• Shares owned after transaction: Not specified in the filing excerpt provided.
• Footnote: Each RSU is a contingent right to one share of common stock and "shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service through such vesting date."
• No 10b5-1 plan, tax-withholding, or sale noted in this filing.

Context RSUs are compensation awards that convert to actual shares only upon vesting and settlement; they do not represent immediate stock purchases or sales. Grants to directors are common as part of compensation programs and are not direct market transactions indicating buying or selling intent.